Page 852 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

830 Index

Metabolite, 347 Minimum database, of intracranial tumors, Multiple cartilaginous exostosis (MCE),
660
552–553, 552f
Metal endoprosthesis, for canine Mitosis Multiple myeloma, 740–748
osteosarcoma, 537, 538f
VetBooks.ir Metallic implant, sarcoma and, 17 G 1 /G 2 phase and, 210 diagnosis and staging, 741f–744f, 744–746,
nonproliferating cells and, 36
Metalloprotease, 52–53
745t
Metaphase, 36 phases of, 36 differential diagnosis, 746
preparation, from chromosomes, 147 somatic cells and, 36 imaging, 745
Metaplasia, 62–63 Mitotane immunohistochemical and molecular
Metastasectomy, 168 for canine adrenocortical tumors, 572 diagnostics, 744–745
Metastasis, 36–60 for canine pituitary-dependent history and clinical signs, 743–744, 744t
angiogenesis and, 54–55 hypercortisolism, 567 hypercalcemia of malignancy and, 100
bone marrow-derived cells and, 7 Mitotic figures, 65–66, 66t incidence and etiology, 740
cutaneous SCC and, 357 Mitotic index pathology and natural behavior, 740–743,
definition of, 51 mast cell tumors and, 385–386 741f–743f
epithelial-to-mesenchymal transition role molecular mechanism for, 69t prognosis, 748, 749f, 749t
in, 7 Mitoxantrone, 193 in spinal cord, 666t
of feline sarcoma, 424 for urinary bladder tumors, 649t–650t treatment, 746–748
host gene and, 55 Modified Wright stain, 128–129 evaluation of response to therapy,
in lymph nodes, identification of, 141 Molecular diagnostics, 146–157 746–747, 747f
from metastases, 47–48 as clinician, 155 initial therapy, 746
process of, 51–56 definition of, 146 investigational therapies, 748
Metastasis-associated gene, 51–52 goals of, 146 rescue therapy, 748
Metastasis suppressor gene, 51–52 for prognosis, 146 therapy directed at complications,
Metastatic cancer, 53 Molecular profiling 747–748
Metastatic cascade, 52f prognostic evaluation and, 198 Multiple papillomatosis
epithelial-to-mesenchymal transition and, purpose of, 347 site for, 20
53 tumor sensitivity and, 198 view of, 20f
Metastatic cell, 54 Molecular targeted therapies, for canine Multistep carcinogenesis, 40–41
Metastatic colon cancer, 169 osteosarcoma, 545–546 Muscle mass scoring system (MMS), 304t
Metastatic inefficiency, 55 Molecular targeted agent, 342 Mutation
Metastatic phenotype, carcinogenesis and, 55 Monoclonal antibody (MAb), 240–241 internal tandem duplication (ITD) and,
Methimazole, for feline hyperthyroidism, conjugated, 241 259–260
578–579 humanized, 261–262 KIT, 260
Methotrexate, 193–194 molecular profiling and, 347 Mutator phenotype, 7
uptake, 184 Monoclonal gammopathy, 102 MVD. see Microvessel density
Methylation Monomorphic cell, 130–131 MWA. see Microwave ablation
of DNA, 269–272 Morphine, 299t Myasthenia gravis
gene silencing and, 10 Mortality rate cause of, 106
Metronomic chemotherapy, 265 statistics on, 85 signs and treatment of, 106
biomarkers for, 268 waste sites and cancer, 92 tumors associated with, 99b
mechanisms of action, 265–266 Mortality stage 1 (M1), 46–47 Myc gene, 43
Metronomic therapies, conventional Mortality stage 2 (M2), 46–47 MYC locus, 12
chemotherapy combined with, in canine Mott cell, 142 Mycobacterium bovis, 236
osteosarcoma, 544 Mouse double minute 2 oncogene (MDM2), Myeloid-derived suppressor cell (MDSC)
MH. see Malignant histiocytosis role of, 38 antitumor response, suppression of, 233
Microangiopathic hemolytic anemia MRI. see Magnetic resonance imaging depletion of immunosuppressive, 235
(MAHA), 103 MST. see Median survival time immune suppression by, 233
Microarrays, 153, 153f MTD. see Maximum tolerated dose immunotherapy and suppression of, 233
Microenvironment mTOR, 262 tumor immunosuppression by, 233
of secondary metastasis, 54 Mucin, 130 Myeloid tumor, FIV infection and, 25
of tumor cell, 49–50 Multicentric FeSV-induced tumor, 25 Myelolipoma, 456
adaptive evolution and, 9–10 Multicentric papillomavirus-induced SCC, Myeloma-related disorders, 739–752, 740b
immunosuppressive barrier, 9 357 multiple myeloma, 740–748
Microenvironmental-derived growth factor, Multidrug resistant (MDR), 185–186 diagnosis and staging, 741f–744f,
47–48 Multifocal nodules, ultrasonography of, 115f 744–746
Micrometastasis, 52f Multilobular bone tumor, 140 history and clinical signs, 743–744,
Microscope, 129 Multilobular osteochondrosarcoma, 447 744t
Microvessel density (MVD), 628 CT image of, 447f incidence and etiology, 740
Microwave ablation (MWA), 179 in dogs, 551–552, 551f pathology and natural behavior,
Mineralization, in adrenal gland neoplasia, features of importance and grades for, 68t 740–743, 741f–743f
571–572 Multinodular adenomatous hyperplasia, 577 prognosis, 748, 749f, 749t
Minimum alveolar concentration (MAC), 298 Multinucleated tumor cell, 140f treatment, 746–748